跳至主要内容
临床试验/EUCTR2020-004777-49-AT
EUCTR2020-004777-49-AT进行中(未招募)1 期

A prospective, observational long-term follow-up trial of kidney transplant patients treated with imlifidase or plasma exchange after an active/chronic active Antibody-Mediated Rejection episode

Hansa Biopharma0 个研究点目标入组 30 人开始时间: 2020年12月17日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Signed Informed Consent obtained before any trial-related procedures
  • Willingness and ability to comply with the protocol
  • Previous treatment with imlifidase or plasma exchange in trial 16-HMedIdeS-12
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • Inability by the judgement of the investigator to participate in the trial for any other reason

研究者

发起方
Hansa Biopharma

相似试验